Michael Van Kampen
- 4.5 Good • 52 reviews
- 36 years of experience
- Germany, Frankfurt am Main, Nordwest Clinic (Krankenhaus)
- Radiotherapy specialist
Education
09 / 2004 – 07 / 2006 Movie Director School, ANT1 Movie School Athens, Greece, Degree “Television Director”, grade point average: B
09 / 2006 – 08 / 2008 Medical School, Semmelweis University Budapest, Hungary, Medical preliminary examination (Physikum), grade point average: A
10 / 2008 – 05 / 2013 Medical School, Albert-Ludwigs-Universität Freiburg, Germany, State examination in medicine, grade point average: A
02/ 2009 – 02/2012 Institute of Pharamcology and Toxicology I, Albert-Ludwigs-Universität Freiburg, Germany, Doctoral thesis, grade: summa cum laude
05 / 2018 Basic and advanced course in German drug law and GCP, Clinical Trials Unit, Medical Center - University of Freiburg
01 / 2019 Board certification: Radiotherapy and Radiation Oncology
03 / 2020 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Habilitation (Postdoctoral lecture qualification)
09 / 21 – 08 / 23 MHBA, Friedrich Alexander University, Nuernberg, Germany
07 / 2022 Completion of ISO 9001:2015 training, Nicosia, Cyprus
Professional Career
09 / 2013 – 01 / 2019 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Residency
07 / 2017 – 07 / 2020 Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Clinician Scientist
Since 06 / 2019 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Consultant
01 / 2021 – 12 / 2022 Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Advanced Clinician Scientist
01 / 2021 – 12 / 2021 Head of the section “Interventional Radiation Oncology”, Medical Center University of Freiburg, Department of Radiation Oncology, Germany
Since 01 / 2022 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Prostate cancer research group leader
Since 01 / 2022 German Medical Institute, Limassol, Cyprus, Vice Medical Director
Professional Memberships and Distinctions
2010 Sanofi-Aventis poster prize, Annual meeting of the German Society of Pharmacology and Toxicology 2010, Mainz, Germany
2017 Poster prize, Annual meeting of the German Society of Radiation Oncology (DEGRO) 2017, Berlin, Germany
2019 Poster prize, Uro-Oncological Symposium 2019, Magdeburg, Germany
2020 Invited member of the German expert panel for prostate cancer of the German Society of Radiation Oncology (DEGRO)
2020 Herman-Holthusen Award, German Society of Radiation Oncology (DEGRO)
2021 Invited member of the ESTRO-ACROP guideline committee for prostate cancer
2021 Best Abstract, EMUC congress 2021, Athens, Greece
2023 Annual ARO study price for the HypoFocal-SBRT study from the German Cancer Foundation
2023 Invited member of the ESTRO focus group “Urology”
Professional experience:
04.2009 – 04.2013: Resident in the Department for Radiation Oncology, Klinikum Offenbach
05.2013 – 12. 2015: Senior physician in the Department for Radiation Oncology, Klinikum Offenbach
Known Expertise
Medical Oncologist
Academic Position
Senior Lecturer
Education
Bar-Ilan University, Israel / Computational Biology
Israeli Society for Health-Tech / Fellowship by IMA/ Innovation and Entrepreneurship in Medicine and Health-Tech
Sheba Medical Center and Bar-Ilan University, Israel/ Genomics and Biomedical Informatics
Semmelweis University/Doctor of Medicine
Training and Specialization
Clinical observership in acute oncology, early phase clinical trials and lung cancer/ Guy's and St. Thomas hospital, London, England
Leader Shift, Executive Development Program, Tel-Aviv Sourasky Medical Center
Fellowship Program in Innovation and Entrepreneurship in Medicine and Health-Tech
Resident, Medical Oncology, TASMC, Israel
6th year medical school rotations, Kaplan Medical Center, Israel
Rotation, intensive care unit and pulmonology, Stony Brook hospital, NY, US
Clinical Experience
Leader of the TASMC oncology project of PSIFAS, the Israeli National Genomic Medicine Initiative
PI for study initiator trial: T-Cell Repertoire sequencing as clinical efficacy tool for pembrolizumab (with platinum based chemotherapy) in advanced NSCLC.
PI for study initiator trial: T-cell repertoire sequencing as a clinically efficacy tool for neoadjuvant immunotherapy plus platinum-doublet chemotherapy for resectable NSCLC.
Representative of the National Medical Association for the National Council for the Prevention, Diagnosis and Treatment of Malignant Diseases, as well as head of the oncology field, Leumit HMO
Consultant on drugs and operations in the field of oncology, Leumit HMO
Member of the Helsinki Committee for Clinical Studies, TASMC
Primary investigator (PI) in pharmaceutical phases I&III clinical trials Head of oncology day-care service, TASMC, Israel
Molecular Tumor Board (MTB) moderator of the Israeli Lung Cancer Society
NGS interpretation clinic alongside head of pathology, TASMC, Israel
PI for study initiator trial: Genomic Variant of BCL-2 as a Novel Predictor of Response to Paclitaxel, TASMC, Israel
Medical oncology clinic in the field of lung and breast cancer, TASMC, Israel
Leading sub-investigator (SI) in many phase I-III clinical trials in oncology, including intra-tumoral injections (mRNA, viruses and NO), TASMC, Israel
Courses
Good Clinical Practice ICH GCP R2 & Israeli MOH Guidelines Updated Course
Point-of-Care Ultrasound course, Israeli Medical Association
GCP training Bioforum
GCP training Bioforum
Investigator Site Personnel ICH GCP Training Certificate - TransCelerate BioPharma
Academic Experience
Lecturer in the Department of Medical Education at the Faculty of Medical and Health Sciences at Tel Aviv University
JIMS Journal Club - Instructor for students.
Guidance of Dr. Aviv Berkovich M.D in basic science: cfDNA NGS for identification ofprimary and acquired resistance in patients with Lung Cancer and EGFR mutations.
TASMC, Israel in collaboration with The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, NY USA
Training team for oncology residents, TASMC, Israel
Mentor for new intern, TASMC, Israel
Tutor for medical students in oncology clerkships, Tel-Aviv University, Israel
Honors
Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel
Outstanding teacher in the faculty of medicine, Tel-Aviv University, Israel
Sign of honor for reserve medical personnel for the battle in Lebanon, IDF
Completion of residency final examination (shlav Beit) with honors
Israeli society for clinical oncology and radiation therapy (ISCORT) 17 research grant competition winner
Affiliations
Israeli Medical Association (IMA)
Israeli Society for Clinical Oncology and Radiation Therapy (ISCORT)
The Israeli Lung Cancer Group (ILCG)
European Society of Medical Oncology (ESMO)
International Association for the Study of Lung Cancer (IASLC)
The International Society of Liquid Biopsy (ISLB)
The Israeli Society for Health-Tech
Boards
Co-founder, board member and treasurer of the Israeli Acute Oncology Society
Clinical Research Association Board of Directors on behalf of the Israeli Lung Cancer Group
Member of the Trustees of Oncology Innovation, TASMC, Israel
Doctor of Medical Service IDF
Areas of interest
Thoracic malignancies,
early to late phase clinical trials,
intra-tumoral injections,
comprehensive genomic profiling of tumors,
liquid biopsies: cfDNA, TCR rep-seq and epi-Genetics;
cell therapy
Dr. Ido Wolf is a specialist in Oncology, Internal Medicine, and the Army Medical Units with a degree from Ben Gurion University of the Negev. He is currently the Head of the Medical Oncology Division at Sourasky Medical Center and speaks English.
Dr. Michael Shapira is a specialist in Bone Marrow Transplantation with over 20 years of experience. He graduated from the Hebrew University Medical School in 1999. He completed his training in internal medicine at Hadassah Medical Center.
Dr. Shapira is a senior physician in the Bone Marrow Transplantation department at Hadassah. He has played a key role in many successful transplants and has helped maintain high patient survival rates. He is known for his clinical skills and commitment to improving transplantation medicine.
Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.
Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.
Dr. Dror Levin is a senior pediatrician and director of the blood disorder and bone cancer (sarcoma) treatment departments at Children's Hospital "Dana" and Medical Center "Sourasky" respectively. He is a specialist in pediatric medicine, hematology, and oncology, with additional experience studying abroad at the Rizzoli Orthopaedic Institute in Italy.
Education/Residency:
Dr. Tatyana Rabin's research interests include:
Methods of destruction of malignant neoplasms by heating with the help of ultrasonic waves, research into the use of brachytherapy in the treatment of oncogynecological diseases,
study of the mechanisms of response at the molecular level of prostate tumor cells to radiotherapy;
clinical studies of oncomammology, oncopulmonology, ocular lymphoma.
Dr. Rabin is investigating the molecular mechanisms by which prostate cancer cells respond to radiation therapy. This research is being conducted in collaboration with the Weizmann Institute of Science.
In addition, Dr. Rabin has been involved in clinical research in the areas of breast cancer, lung cancer, and ocular lymphoma.
Dr. Rabin is currently coordinating a new and unique study at Sheba Hospital that is investigating a method of treating cancerous tumors using MRI-guided ultrasound waves. This method involves raising the tumor's temperature to a certain level and then destroying it.
Awards:
Dr. Tatyana Rabin was recognized as the best hospital employee for 2007.
Experience and participation in scientific research:
Membership in medical societies :
Director of Radiotherapy Institute Oncology Division
Dr. Rashad Rzazade is a skilled radiation oncologist. He specializes in advanced cancer treatments, including IMRT, SRT, proton therapy, and CyberKnife. He has strong experience treating head and neck cancers, brain tumors, lung, spine, cervical, and gastrointestinal cancers.
Dr. Rzazade trained at Azerbaijan Medical School, Hacettepe University, and Marmara University. He also gained international experience at MD Anderson Cancer Center. He has treated thousands of patients and is known for high survival rates and patient satisfaction in complex cancer cases.
Pediatric Hematology and Oncology / Pediatric Oncology
Pediatric Hematology and Oncology
2010 - 2012
M. Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital
2002 - 2010
Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
1993 - 1998
İ.Ü. Istanbul Faculty of Medicine
Dr. Viola Fox is the Chief Physician at the Clinic for Haematology, Oncology, and Palliative Medicine at BKZ Solingen. This clinic is a certified interdisciplinary cancer center. Dr. Fox is a leading expert in drug therapy for tumor diseases in Germany and Europe. She has more than 15 years of experience in this field.
She is a member of the German Society of Oncology and Haemato-oncology (GDHO), the German Association of Physicians, and the American Association for Cancer Research. Dr. Fox is also active in molecular biology research. Her work supports progress in cancer treatment and molecular diagnostics.
Her main areas of expertise are chemotherapy, immunotherapy, targeted therapy, and radiation therapy. Dr. Fox is known for her innovative methods and strong commitment to patient care. Her efforts have led to high recovery rates and recognition from her peers.